Official Title
PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
Brief Summary

To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease

Detailed Description

An observational, retrospective, case-controlled study to determine the status of IBD during
development of COVID-19 symptoms/positive COVID-19. The aim is to describe the adaptations in
therapies for active IBD during SARS COV 2 in patients with active IBD and positive or
negative COVID-19 symptoms. It will evaluate IBD outcomes following development of COVID-19
symptoms / positive COVID-19 and determine any predictors of outcomes in IBD patients with
COVID-19 symptoms / positive COVID-19 as well as determine the impact on IBD outcomes
resulting from adaptations to treatments during COVID-19

Completed
Inflammatory Bowel Diseases
Coronavirus Infection
Eligibility Criteria

Inclusion Criteria:

- Patients with IBD +/- flare +/- COVID 19 positivity

Exclusion Criteria:

- Patients below 16

- Patient with inactive IBD

Eligibility Gender
All
Eligibility Age
Minimum: 16 Years ~ Maximum: 100 Years
Countries
United Kingdom
Locations

Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust
Hull, United Kingdom

Shaji Sebastian, Principal Investigator
Hull and East Yorkshire NHS Trust

Hull University Teaching Hospitals NHS Trust
NCT Number
MeSH Terms
Coronavirus Infections
COVID-19
Intestinal Diseases
Inflammatory Bowel Diseases